Pablo Legorreta, Royalty Pharma CEO (Patrick T. Fallon/Bloomberg via Getty Images)
Royalty Pharma execs shed light on strategy behind their first gene therapy deal
A deal with Ferring Pharmaceuticals last month represented Royalty Pharma’s first foray into gene therapy royalties, and it’s already raising questions about whether it represents a shift in the company’s philosophy.
CEO Pablo Legorreta and other Royalty execs addressed the topic for the first time Tuesday at Morgan Stanley’s healthcare conference in New York. While they’re excited about the Ferring deal, they suggested that much of the strategy that’s guided Royalty for its nearly three-decade existence will remain the same.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
